QL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
QL04 IMMUNOSUPPRESSANTS
QL04A IMMUNOSUPPRESSANTS
QL04AJ Complement inhibitors
QL04AJ02 ravulizumab
Last updated: 2024-12-27
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway
Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway
Tel: +47 21 07 81 60
E-mail:
Copyright/Disclaimer
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway
Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway
Tel: +47 21 07 81 60
E-mail:
Copyright/Disclaimer